Our goal is to be the “Preferred Partner” for pharmaceutical companies, academic institutions, governmental agencies, patient foundations and entrepreneurs seeking a partner to collaborate on the development and commercialization of therapies for patients suffering from rare diseases. We have a long established and successful track record, and are able to enter into collaborations quickly and professionally.

Please contact:

Nancy Klett


What is the Orphan Drug Act of 1983?

The U.S. Orphan Drug Act was passed in 1983 and signed into law by President Ronald Reagan. The legislation gives incentives to pharmaceutical companies to develop drugs, biologics, or other therapeutics that will treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug law offers tax breaks and a seven-year period of market exclusivity to help support the development and manufacturing of such products, which are often difficulty to financially support because of the small potential market. Since the passage of the law nearly 350 new medicines have been approved to treat rare disease. Prior to the passage of the Act less than 10 medicines were approved for rare disease indications.